⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147809 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3273038 | 0.98 | SMARCA2 (0.49) | — | |
| SCHEMBL30851415 | 0.77 | — | — | |
| SCHEMBL883720 | 0.77 | — | — | |
| SCHEMBL16870255 | 0.77 | SMARCA2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL16860817 | 0.76 | SMARCA2 (0.50) | — | |
| SCHEMBL20748625 | 0.75 | KDM4E (0.56) | — | |
| SCHEMBL13407710 | 0.75 | IDO1 (0.57) | — | |
| SCHEMBL1759892 | 0.74 | GOT1 (0.37) | — | |
| SCHEMBL19030966 | 0.74 | LOX (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041252-A | A kind of preparation method of the chloro- 4- hydrazino pyridine of 2- | 南京合巨药业有限公司 | 2019-07-23 | — | — | CN | claimed |
| CN-118324741-A | Pyrazole ether compound as well as preparation method and application thereof | 南通泰禾化工股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| EP-3807266-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-1747949-A | Acyclic pyrazole compounds | PHARMACIA CORP (US) | 2006-03-15 | — | — | CN | disclosed |
| CN-1738615-A | Diaminotriazoles as inhibitors of protein kinases | VERTEX PHARMA (US) | 2006-02-22 | — | — | CN | disclosed |
| US-20050261268-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-11-24 | — | — | US | disclosed |
| EP-1572682-A2 | ACYCLIC PYRAZOLE COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1562589-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005013982-A1 | AMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-28 | — | — | US | disclosed |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004058176-A2 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004046120-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-06-03 | — | — | WO | disclosed |